<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02320045</url>
  </required_header>
  <id_info>
    <org_study_id>ITCA 650 CLP-109</org_study_id>
    <nct_id>NCT02320045</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetics of ITCA 650 in Subjects With Mild and Moderate Renal Impairment Compared to the Pharmacokinetics of Subjects With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1 study to evaluate the pharmacokinetics of ITCA 650 in subjects with mild and
      moderate renal impairment compared to the pharmacokinetics of subjects with normal renal
      function
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-h Area under the Curve at steady state (AUCt,ss)</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of adverse events</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety laboratory parameters</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical exam</measure>
    <time_frame>Approximately 67 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Group 1: Normal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Mild Renal Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Goup 3: Moderate Renal Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Moderate Renal Dysfunction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) &gt;30-44 mL/min/1.73 m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITCA 650 (Exenatide in osmotic mini pump)</intervention_name>
    <arm_group_label>Group 1: Normal</arm_group_label>
    <arm_group_label>Group 2: Mild Renal Dysfunction</arm_group_label>
    <arm_group_label>Goup 3: Moderate Renal Dysfunction</arm_group_label>
    <arm_group_label>Group 4: Moderate Renal Dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index between 22 and 40 kg/m²

          -  Subjects meeting pre-defined estimated glomerular filtration rate criteria and
             creatinine clearance rate

               -  Normal (≥90 mL/min/1.73 m2)

               -  Mild (60-89 mL/min/1.73 m2)

               -  Moderate (45-59 mL/min/1.73 m2)

               -  Moderate (&gt;30-44 mL/min/1.73 m2)

        Exclusion Criteria:

          -  History of acute metabolic complications

          -  Uncontrolled Hypertension

          -  History of Hypersensitivity to Exenatide

          -  Cardiovascular Disease

          -  History of Acute or chronic pancreatitis

          -  Personal or family history of Multiple endocrine neoplasia type 2

          -  History of Medullary thyroid cancer

          -  Severe renal failure, End stage renal disease or dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intarcia Therapeutics Inc.</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Moenchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2014</study_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

